Fosfomycin Disk Diffusion Testing among Klebsiella pneumoniae Results in Frequent Inner Colonies and Categorical Disagreement Based on Conflicting Breakpoint Organization Recommendations

被引:5
作者
Bixby, Morgan L. [1 ]
Salay, Jenna M. [1 ]
Krueger, Amanda R. [1 ]
Mathers, Amy J. [2 ]
Hirsch, Elizabeth B. [1 ]
机构
[1] Univ Minnesota, Coll Pharm, Minneapolis, MN 55455 USA
[2] Univ Virginia, Dept Med & Pathol, Charlottesville, VA USA
关键词
fosfomycin; disk diffusion; inner colonies; agreement; interpretation; Klebsiella pneumoniae; URINARY-TRACT-INFECTIONS; SUSCEPTIBILITY; ENTEROBACTERALES; RESISTANCE; MECHANISMS; IMPACT;
D O I
10.1128/spectrum.03363-22
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Fosfomycin susceptibility testing recommendations are complex. Both the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recognize agar dilution as the reference method, but they also support disk diffusion as an approved method for Escherichia coli. Recent studies indicate that discrete inner colonies (ICs) arise during fosfomycin disk diffusion (DD) testing. CLSI and EUCAST have contradicting recommendations on the interpretation of ICs; CLSI recommends considering them while EUCAST recommends ignoring them when interpreting DD results. We sought to compare the categorical agreement of DD and agar dilution (AD) MIC and to assess the implications of ICs interpretation on zone diameter readings. A convenience sample of 80 Klebsiella pneumoniae clinical isolates with varied phenotypic profiles collected from 3 United States locations was included. Susceptibility was determined in duplicate, using both organization recommendations and interpretations for Enterobacterales. Correlations between methods were calculated using EUCAST(IV) AD as the reference method. MIC values ranged from 1 to >256 mu g/mL with an MIC50/90 of 32/256 mu g/mL. Extrapolating EUCAST(oral) and CLSI AD Escherichia coli breakpoints, 12.5% and 83.8% of isolates were susceptible, respectively, whereas 66.3% were susceptible by EUCAST(IV) AD-which applies to K. pneumoniae. CLSI DD measurements were 2 to 13 mm smaller than EUCAST measurements due to 66 (82.5%) isolates producing discrete ICs. Categorical agreement with EUCAST(IV) AD was greatest for CLSI AD (65.0%) and poorest for EUCAST(oral) DD (6.3%). Isolates among this collection were frequently classified into different interpretive categories based on varying breakpoint organization recommendations. The more conservative oral breakpoints of EUCAST resulted in more isolates categorized as resistant despite frequent ICs. Differing zone diameter distributions and poor categorical agreement highlight issues of extrapolating E. coli breakpoints and methods to other Enterobacterales, and the clinical relevance of this issue warrants further investigation.IMPORTANCE Fosfomycin susceptibility testing recommendations are complex. Both the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) recognize agar dilution as the reference method, but they also support disk diffusion as an approved method for Escherichia coli. However, these two organizations have conflicting recommendations for the interpretation of inner colonies that arise during disk diffusion testing which can lead to varying zone diameters and interpretations despite isolates having identical MIC values. Using a collection of 80 Klebsiella pneumoniae isolates, we found that a large (82.5%) portion produced discrete inner colonies during disk diffusion and isolates were frequently classified into different interpretive categories. The more conservative breakpoints of EUCAST resulted in more isolates categorized as resistant despite frequent inner colonies. Differing zone diameter distributions and poor categorical agreement highlight issues of extrapolating E. coli breakpoints and methods to other Enterobacterales, and the clinical relevance of this issue warrants further investigation.
引用
收藏
页数:8
相关论文
共 29 条
  • [1] Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints
    Abbott, Iain J.
    Mouton, Johan W.
    Peleg, Anton Y.
    Meletiadis, Joseph
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (12) : 3201 - 3211
  • [2] Impact of bacterial species and baseline resistance on fosfomycin efficacy in urinary tract infections
    Abbott, Iain J.
    Dekker, Jordy
    van Gorp, Elke
    Wijma, Rixt A.
    Raaphorst, Merel N.
    Klaassen, Corne H. W.
    Meletiadis, Joseph
    Mouton, Johan W.
    Peleg, Anton Y.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (04) : 988 - 996
  • [3] Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome
    Abbott, Iain J.
    van Gorp, Elke
    Wijma, Rixt A.
    Meletiadis, Joseph
    Roberts, Jason A.
    Mouton, Johan W.
    Peleg, Anton Y.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (03)
  • [4] Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature
    Babiker, Ahmed
    Clarke, Lloyd
    Doi, Yohei
    Shields, Ryan K.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2019, 95 (03)
  • [5] Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance
    Castaneda-Garcia, Alfredo
    Blazquez, Jesus
    Rodriguez-Rojas, Alexandro
    [J]. ANTIBIOTICS-BASEL, 2013, 2 (02): : 217 - 236
  • [6] Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline
    Chen, Alice
    Smith, Kenneth P.
    Whitfield, Betsy A.
    Zucchi, Paola C.
    Lasco, Todd M.
    Bias, Tiffany E.
    Kirby, James E.
    Hirsch, Elizabeth B.
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 88 (04) : 365 - 367
  • [7] Clinical and Laboratory Standards Institute, 2022, PERFORMANCE STANDARD
  • [8] Clinical and Laboratory Standards Institute, 2018, DEV IN VITR SUSC TES
  • [9] The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical Isolates
    Elliott, Zachary S.
    Barry, Katie E.
    Cox, Heather L.
    Stoesser, Nicole
    Carroll, Joanne
    Vegesana, Kasi
    Kotay, Shireen
    Sheppard, Anna E.
    Wailan, Alex
    Crook, Derrick W.
    Parikh, Hardik
    Mathers, Amy J.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (10)
  • [10] European Committee on Antimicrobial Susceptibility Testing, 2020, FOSF TROM RAT EUCAST